Related Experiment Videos
[Lipid profile during specific malaria therapy in Gabonese children]
E Ngou-Milama1, T H Duong, F Minko
1Faculté de Médecine, Service parasitologie-médecine tropicale, Tours, France.
Sante (Montrouge, France)
|March 1, 1995
Summary
Malaria treatment with Halfan in Gabonese children caused specific dyslipidemia, including altered high-density lipoprotein and triglyceride levels. This metabolic variation occurred alongside typical malaria-associated hypoglycemia.
Area of Science:
- Pediatric infectious diseases
- Clinical biochemistry
- Pharmacology
Context:
- Malaria remains a significant health concern in Gabonese children.
- Halfan (artesunate-sulfadoxine-pyrimethamine) is a common antimalarial treatment.
- Malaria is often associated with hypoglycemia in young children.
Purpose:
- To investigate the lipid profile changes in Gabonese children treated with Halfan for malaria.
- To assess the metabolic variations and tolerance to Halfan in this pediatric population.
Summary:
- Children aged 18 months to 4 years in Gabon receiving Halfan for malaria exhibited specific dyslipidemia.
- High-density lipoprotein (HDL) levels decreased initially then increased during treatment.
- Triglycerides (TG), total cholesterol (TC), and non-esterified fatty acids (NEFA) increased at the start of treatment, with TC rising throughout and TG declining.
- These metabolic changes were statistically significant compared to normal values.
- Hypoglycemia was also observed, consistent with malaria.
Impact:
- Highlights potential metabolic side effects of Halfan treatment in pediatric malaria patients.
- Informs clinical monitoring and management strategies for children undergoing antimalarial therapy.
- Contributes to understanding drug-induced metabolic alterations in a vulnerable population.